Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_3
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 31 (100.0%)

Trials by Status

recruiting267%
active_not_recruiting133%

Recent Activity

3 active trials
Showing 3 of 3
recruiting

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

NCT07758270
active_not_recruitingphase_3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343
recruiting

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

NCT07207148

Clinical Trials (3)

Showing 3 of 3 trials
NCT07758270

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Recruiting
NCT06700343Phase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Active Not Recruiting
NCT07207148

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3